scholarly journals Controlling cardiac fibrosis through fibroblast state space modulation

2021 ◽  
Vol 79 ◽  
pp. 109888
Author(s):  
Isabella M. Reichardt ◽  
Kalen Z. Robeson ◽  
Michael Regnier ◽  
Jennifer Davis
1991 ◽  
Vol 138 (1) ◽  
pp. 50 ◽  
Author(s):  
Leang S. Shieh ◽  
Xiao M. Zhao ◽  
John W. Sunkel
Keyword(s):  

2013 ◽  
Vol 58 (11) ◽  
pp. 1084-1091
Author(s):  
Yu.V. Bezvershenko ◽  
◽  
P.I. Holod ◽  

2009 ◽  
Vol 129 (12) ◽  
pp. 1187-1194 ◽  
Author(s):  
Jorge Ivan Medina Martinez ◽  
Kazushi Nakano ◽  
Kohji Higuchi

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.


Sign in / Sign up

Export Citation Format

Share Document